Skip to content

Clinical Evaluation of Dexmedetomidine in Improving Long-Term Prognosis of Children with ADHD by Regulating Circadian Rhythm Disorders

Clinical Evaluation of Dexmedetomidine in Improving Long-Term Prognosis of Children with ADHD by Regulating Circadian Rhythm Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127810
Enrollment
Unknown
Registered
2026-07-08
Start date
2026-07-10
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD with sleep-wake rhythm disorder

Interventions

Intervention group:On the basis of the original rehabilitation treatment and daytime oral medication treatment, for three consecutive days, at 22:00, dexmedetomidine at a dose of 1 µ g/kg was sprayed
Control Group:On the basis of the original rehabilitation treatment and daytime oral medication, for three consecutive days, at 22:00, nasal spray 1 µ g/kg of normal saline. Divide the total volume of

Sponsors

Wuhan Childrens Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with ADHD using the DSM-5 criteria 2.Gender is not limited. Age: 6 to 12 years old. 3.ASA classification grades I - II; 4. ADHD patients diagnosed with sleep-wake rhythm disorder using the Early Morning and Nighttime Scale (MEQ-19) <40; 5. The guardian of the patient voluntarily accepted the relevant treatment plan of this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Individuals allergic to DEX; 2.Combining special diseases such as sleep apnea syndrome, restless leg syndrome, or somatic pain that can easily cause insomnia; 3.Those who are not suitable for nasal spray administration due to severe rhinitis, nasal malformation, severe asthma, etc; 4.Individuals with heart conduction block or cardiac dysfunction detected by dynamic electrocardiogram examination; 5.After admission, routine examination revealed the presence of other serious organic diseases and mental illnesses; 6.Other individuals who do not meet the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Sleep quality;

Secondary

MeasureTime frame
Score of the Attention Deficit Hyperactivity Disorder Screening Scale (SNAP-IV);The content of melatonin in blood and saliva;The content of brain-derived neurotrophic factor (BDNF) in blood;Circadian rhythms;Safety evaluation;

Countries

China

Contacts

Public ContactKong Fanli

Wuhan Childrens Hospital

40705521@qq.com+86 27 82300131

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026